Shots: NICE concludes that the ICER Yescarta vs salvage CT were above £50,000 per year making it expensive for use NICE also added considering ultra-orphan diseases that ICER for Yescarta was over £100,000 per QALY (Quality Adjusted Life) Consideration of making Yescarta available via Cancer Drug Funds has also been dropped by the committee. Consultation […]Read More
Tags : Expensive
Latest Posts
Categories
Related Topics
AbbVie
Acquire
Adults
Agreement
Amgen
approval
AstraZeneca
Bayer
Biosimilar
BMS
Collaborate
Collaborates
Collaboration
Commercialize
COVID-19
Develop
Development
Eli Lilly
EU
Exclusive
FDA
Gilead
GSK
Janssen
Launches
License
License Agreement
Merck
Novartis
P-III
patients
Pfizer
receives
Report
reports
results
Roche
Sanofi
Signs
study
Takeda
the US FDA
Treat
Treatment
US